journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lymphoma, Myeloma & Leukemia

journal
https://www.readbyqxmd.com/read/29653823/-society-of-hematologic-oncology-soho-state-of-the-art-updates-and-next-questions-treatment-of-all
#1
REVIEW
Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer
The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits...
April 3, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29605422/leukocytoclastic-vasculitis-and-desensitization-to-high-dose-methotrexate-in-primary-central-nervous-system-lymphoma
#2
Colette Hanna, Diego Villa, Carla Irani, Marwan Ghosn, Elie El Rassy
No abstract text is available yet for this article.
March 19, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29606369/various-signaling-pathways-in-multiple-myeloma-cells-and-effects-of-treatment-on-these-pathways
#3
REVIEW
Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad
Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages > 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development of drug resistance. The tumor cells develop resistance to apoptosis, resulting in greater cell survival, and, ultimately, develop drug resistance by changing the various signaling pathways involved in cell proliferation, survival, differentiation, and apoptosis...
March 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29625928/serum-free-light-chain-difference-and-%C3%AE-2-microglobulin-levels-are-risk-factors-for-thromboembolic-events-in-patients-with-al-amyloidosis
#4
Hyunkyung Park, Ji-Won Kim, Jeonghwan Youk, Youngil Koh, Jeong-Ok Lee, Ki Hwan Kim, Soo-Mee Bang, Inho Kim, Seonyang Park, Sung-Soo Yoon
BACKGROUND: AL amyloidosis might increase the risk of thromboembolism and other plasma cell dyscrasias; however, only a few reports have described the clinical features of thromboembolism. The present study aimed to elucidate the clinical features of thromboembolic events and to identify the risk factors for these events. MATERIALS AND METHODS: The medical records were retrospectively reviewed to define the clinically significant thromboembolic events. RESULTS: A total of 106 patients with biopsy-proven AL amyloidosis were included...
March 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29625927/tolerance-kinetics-and-depth-of-response-for-subcutaneous-versus-intravenous-administration-of-bortezomib-combination-in-chinese-patients-with-newly-diagnosed-multiple-myeloma
#5
Yan Xu, Shuhui Deng, Xuehan Mao, Gang An, Zengjun Li, Yafei Wang, Mariateresa Fulciniti, Matthew Ho, Jianhong Lin, Weiwei Sui, Wei Liu, Dehui Zou, Shuhua Yi, Wenyang Huang, Hong Liu, Rui Lv, Jian Li, Tingyu Wang, Chenxing Du, Nikhil C Munshi, Lugui Qiu
BACKGROUND: Peripheral neuropathy (PN) is an important toxicity that limits the use of bortezomib (Btz). Attempts to reduce PN have included its subcutaneous (SC) administration. PATIENTS AND METHODS: We retrospectively analyzed 307 patients with newly diagnosed multiple myeloma from a single Chinese center, receiving Btz-based regimens administered either via SC injection (SC group, n = 167) or intravenous (IV) infusion (IV group, n = 140). The efficacy and safety of Btz administration via SC and IV were then compared...
March 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29610029/final-3-year-results-of-the-dasatinib-discontinuation-trial-in-patients-with-chronic-myeloid-leukemia-who-received-dasatinib-as-a-second-line-treatment
#6
Masaya Okada, Jun Imagawa, Hideo Tanaka, Hirohisa Nakamae, Masayuki Hino, Kazunori Murai, Yoji Ishida, Takashi Kumagai, Seiichi Sato, Kazuteru Ohashi, Hisashi Sakamaki, Hisashi Wakita, Nobuhiko Uoshima, Yasunori Nakagawa, Yosuke Minami, Masahiro Ogasawara, Tomoharu Takeoka, Hiroshi Akasaka, Takahiko Utsumi, Naokuni Uike, Tsutomu Sato, Sachiko Ando, Kensuke Usuki, Syuichi Mizuta, Satoshi Hashino, Tetsuhiko Nomura, Masato Shikami, Hisashi Fukutani, Yokiko Ohe, Hiroshi Kosugi, Hirohiko Shibayama, Yasuhiro Maeda, Toshihiro Fukushima, Hirohito Yamazaki, Kazuo Tsubaki, Toshimasa Kukita, Yoko Adachi, Toshiki Nataduka, Hiroto Sakoda, Hisayuki Yokoyama, Takahiro Okamoto, Yukari Shirasugi, Yasushi Onishi, Masaharu Nohgawa, Satoshi Yoshihara, Satoshi Morita, Junichi Sakamoto, Shinya Kimura
INTRODUCTION: We previously reported an interim analysis of the DADI (dasatinib discontinuation) trial. The results showed that 48% of patients with chronic myeloid leukemia in the chronic phase who maintained a deep molecular response (DMR) for ≥ 1 year could discontinue second- or subsequent-line dasatinib treatment safely at a median follow-up of 20 months. However, the results from longer follow-up periods would be much more useful from a clinical perspective. PATIENTS AND METHODS: The DADI trial was a prospective, multicenter trial conducted in Japan...
March 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29656050/an-expanded-treatment-protocol-of-panobinostat-plus-bortezomib-and-dexamethasone-in-patients-with-previously-treated-myeloma
#7
Vincent L Hansen, Morton Coleman, Stephanie Elkins, Jeffrey P Letzer, Moshe Yair Levy, Lasika Seneviratne, Jessica Rine, Marina White, Emil T Kuriakose
BACKGROUND: Panobinostat was recently approved by the US Food and Drug Administration and European Commission in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received ≥ 2 regimens, including bortezomib and an immunomodulatory drug. The PANEX (panobinostat expansion) treatment protocol provided access to panobinostat and gathered additional safety data before commercial availability. PATIENTS AND METHODS: In treatment phase 1, patients received panobinostat 20 mg 3 times per week plus bortezomib 1...
March 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29610030/clinical-implications-of-targeting-xpo1-mediated-nuclear-export-in-multiple-myeloma
#8
REVIEW
Ujjawal H Gandhi, William Senapedis, Erkan Baloglu, Thaddeus J Unger, Ajai Chari, Dan Vogl, Robert F Cornell
Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse is common. Current therapeutic strategies include combination and sequential treatments with corticosteroids, alkylating agents, proteasomal inhibitors, immunomodulators, and monoclonal antibodies. These drugs prolong survival but ultimately become ineffective. Exportin 1 (XPO1), a nuclear export protein, is overexpressed in MM cells, and knockdown studies have suggested that XPO1 is essential for MM cell survival. Selective inhibitor of nuclear export (SINE) compounds are novel, orally bioavailable class of agents that specifically inhibit XPO1...
March 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29605423/treating-adult-acute-lymphoblastic-leukemia-in-brazil-increased-early-mortality-using-a-german-multicenter-acute-lymphoblastic-leukemia-based-regimen
#9
Wellington Fernandes da Silva Junior, Andrezza Bertolaci Medina, Patrícia Eiko Yamakawa, Valéria Buccheri, Elvira D R P Velloso, Vanderson Rocha
BACKGROUND: Acute lymphoblastic leukemia (ALL) in adults is an invariably aggressive and rare disease. Its treatment is based on the use of multidrug regimens, which have been improved since the 1970s. Few published data are available on the results of adult ALL treatment in Latin America. MATERIALS AND METHODS: We retrospectively analyzed the data from 59 patients with ALL treated from 2009 to 2015 at Hospital of Clinics of University of São Paulo, using an adapted German Multicenter ALL (GMALL) protocol (07/2003)...
March 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29574002/treatment-with-jak-inhibitors-in-myelofibrosis-patients-nullifies-the-prognostic-impact-of-unfavorable-cytogenetics
#10
Vincent T Ma, Philip S Boonstra, Kamal Menghrajani, Cecelia Perkins, Krisstina L Gowin, Ruben A Mesa, Jason R Gotlib, Moshe Talpaz
INTRODUCTION: In the era before Janus kinase (JAK) inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown. PATIENTS AND METHODS: We performed a retrospective analysis of 180 patients with bone marrow biopsy-proven myelofibrosis from 3 US academic medical centers. We fit Cox proportional hazards models for overall survival and transformation-free survival on the bases of 3 factors: JAK inhibitor therapy as a time-dependent covariate, dichotomized cytogenetic status (favorable vs...
March 2, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29572159/elderly-patients-age-70-years-or-older-with-secondary-acute-myeloid-leukemia-or-acute-myeloid-leukemia-developed-concurrently-to-another-malignant-disease
#11
Elodie Collinge, Sandrine Loron, Marie-Virginie Larcher, Mohamed Elhamri, Maël Heiblig, Alexandre Deloire, Sophie Ducastelle, Hélène Labussière, Fiorenza Barraco, Eric Wattel, Gilles Salles, Etienne Paubelle, Xavier Thomas
INTRODUCTION: Secondary acute myeloid leukemia (sAML) remains a therapeutic challenge. In elderly patients with AML, it is unclear whether sAML displays an inferior outcome compared with de novo AML. PATIENTS AND METHODS: We studied AML with an antecedent of hematologic disease, treatment-related AML, or AML occurring concurrently to another malignancy in a single-center cohort of patients aged 70 and older with AML. The study included 169 patients who were compared with a cohort of patients with de novo AML, without any prior history of malignant disorders, seen during the same period of time...
March 2, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29572158/a-phase-i-ii-trial-of-the-combination-of-azacitidine-and-gemtuzumab-ozogamicin-for-treatment-of-relapsed-acute-myeloid-leukemia
#12
Bruno C Medeiros, Tiffany N Tanaka, Larisa Balaian, Asad Bashey, Amy Guzdar, Hongying Li, Karen Messer, Edward D Ball
INTRODUCTION: Treatment with hypomethylating agent therapy might enhance anti-CD33 monoclonal antibody-mediated cytotoxicity against acute myeloid leukemia (AML) blasts through epigenetic effects on Syk and SHP-1 expression. PATIENTS AND METHODS: In the present phase I/II study, we treated patients with relapsed or refractory AML with azacitidine, followed by 2 doses of gemtuzumab ozogamicin (GO) at 6 mg/m2 , the Food and Drug Administration-approved dose and schedule at study initiation...
March 2, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29625929/thiotepa-10-mg-kg-treatment-regimen-is-superior-to-thiotepa-5-mg-kg-in-tbf-conditioning-in-patients-undergoing-allogeneic-stem-cell-transplantation
#13
Jean El-Cheikh, Radwan Massoud, Nour Moukalled, Basel Haffar, Hazem Assi, Ammar Zahreddine, Rami Mahfouz, Ali Bazarbachi
INTRODUCTION: The optimal intensity of myeloablation with a reduced-toxicity conditioning regimen to decrease relapse rate after allogeneic stem-cell transplantation without increasing transplant-related mortality (TRM) has not been well established. MATERIALS AND METHODS: We compared outcomes between 5 mg/kg (T5) and 10 mg/kg (T10) thiotepa-based conditioning regimens in 29 adults who underwent allogeneic stem-cell transplantation for hematologic malignancies. RESULTS: After a median follow-up of 11 months, TRM was 0% and 14% at 100 days and 1 year, respectively, with TRM observed only in the T5 group (P = ...
March 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29576386/multiple-myeloma-clinical-updates-from-the-american-society-of-hematology-annual-meeting-2017
#14
REVIEW
Evangelos Terpos
The novel clinical data for myeloma that were presented in the 2017 Annual Meeting of the American Society of Hematology are summarized here. Studies with curative approach (CESAR) or prolonging progression-free survival (CENTAURUS) for patients with high-risk smoldering multiple myeloma (SMM) are described. Updated data from large phase III studies for patients with newly diagnosed MM (NDMM) who are eligible for autologous stem cell transplantation (ASCT) (EMN02, MRC XI) are described, along with the results of studies using novel anti-myeloma drug combinations for induction, consolidation, and maintenance as first-line therapy...
March 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29550108/l-carnitine-and-vitamin-b-complex-for-the-treatment-of-pegasparaginase-induced-hyperbilirubinemia
#15
Caitlin R Rausch, Shilpa Paul, Kayleigh R Marx, Elias Jabbour, Naveen Pemmaraju, Alessandra Ferrajoli, Hagop Kantarjian
No abstract text is available yet for this article.
February 26, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29544762/prognostic-effect-of-cd20-expression-in-adult-b-cell-acute-lymphoblastic-leukemia
#16
Reibán-Espinoza Esteban, Bourlon Christianne, Aguayo Alvaro, Demichelis-Gómez Roberta
INTRODUCTION: The expression of the CD20 on adult B-cell acute lymphoblastic leukemia (ALL-B) has generally been associated with a poor prognosis, and several studies have explored the incorporation of rituximab into the therapeutic regimen for adult ALL-B patients, with a positive effect on event-free survival (EFS). PATIENTS AND METHODS: We analyzed the prognostic value of CD20 expression and the effect of rituximab for the treatment of Hispanic adult ALL-B patients...
February 26, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29472112/abnormal-heavy-light-chain-ratio-and-matched-pair-suppression-increase-residual-disease-detection-sensitivity-in-patients-with-multiple-myeloma-with-deep-responses
#17
Kanji Miyazaki, Kenshi Suzuki
BACKGROUND: Heavy/light chain (HLC) assay can quantify involved as well as uninvolved immunoglobulin pairs and is used to detect monoclonal proteins. PATIENTS AND METHODS: We compared the sensitivity between HLC assay and serum protein electrophoresis, serum immunofixation electrophoresis (IFE), and free light chain (FLC) assay in patients with symptomatic multiple myeloma (n = 111) whose responses were stable disease or better. RESULTS: Among patients with negative IFE and normal FLC ratios, 84...
February 19, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29519619/efficacy-of-ponatinib-versus-earlier-generation-tyrosine-kinase-inhibitors-for-front-line-treatment-of-newly-diagnosed-philadelphia-positive-acute-lymphoblastic-leukemia
#18
Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Nora McCormick, Wendy Y Cheng, Lisa J McGarry, Ariadne Souroutzidis, Hui Huang, Susan O'Brien, Farhad Ravandi, Hagop M Kantarjian
INTRODUCTION: Complete molecular response (CMR) and 2- and 3-year overall survival (OS) were compared for patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who had undergone front-line combination chemotherapy plus ponatinib versus combination therapy plus earlier generation tyrosine kinase inhibitors (TKIs; imatinib, dasatinib, and nilotinib). PATIENTS AND METHODS: We identified 26 Ph+ ALL studies: 25 of earlier generation TKIs and 1 of ponatinib...
February 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29519618/prognostic-prediction-model-for-second-allogeneic-stem-cell-transplantation-in-patients-with-relapsed-acute-myeloid-leukemia-single-center-report
#19
Sung-Soo Park, Hee-Je Kim, Kyoung Il Min, Gi June Min, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min
PURPOSE: To identify factors affecting survival outcomes and to develop a prognostic model for second allogeneic stem-cell transplantation (allo-SCT2) for relapsed acute myeloid leukemia (AML) after the first autologous or allogeneic stem-cell transplantation. PATIENTS AND METHODS: Seventy-eight consecutive adult AML patients who received allo-SCT2 were analyzed in this retrospective study. RESULTS: The 4-year overall survival (OS) rate was 28...
February 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29506935/prognostic-biomarkers-in-the-progression-from-mgus-to-multiple-myeloma-a-systematic-review
#20
REVIEW
Charlotte Cosemans, Bénedith Oben, Ingrid Arijs, Annick Daniëls, Jeroen Declercq, Kimberly Vanhees, Guy Froyen, Brigitte Maes, Jeroen Mebis, Jean-Luc Rummens
Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow, is consistently preceded by asymptomatic premalignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging, and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. In this systematic review we summarize the currently identified clinical, imaging, and genomic biomarkers suggested to increase the progression risk or shown to be differentially expressed/present between both cohorts of patients...
February 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
journal
journal
42898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"